Effects of novel HDAC inhibitors on urothelial carcinoma cells

Effects of novel HDAC inhibitors on urothelial carcinoma cells

Abstract Background Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we...

Full description

Bibliographic Details
Main Authors: Aline Kaletsch, Maria Pinkerneil, Michèle J. Hoffmann, Ananda A. Jaguva Vasudevan, Chenyin Wang, Finn K. Hansen, Constanze Wiek, Helmut Hanenberg, Christoph Gertzen, Holger Gohlke, Matthias U. Kassack, Thomas Kurz, Wolfgang A. Schulz, Günter Niegisch
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Clinical Epigenetics
Subjects:
Histone deacetylase HDAC4
Class IIA HDACs
Histone deacetylase inhibitor
Urothelial bladder cancer
Cell cycle arrest
Online Access:http://link.springer.com/article/10.1186/s13148-018-0531-y

Similar Items

Similar Items